U.S. markets closed
  • S&P 500

    3,978.73
    +37.25 (+0.95%)
     
  • Dow 30

    32,120.28
    +191.66 (+0.60%)
     
  • Nasdaq

    11,434.74
    +170.29 (+1.51%)
     
  • Russell 2000

    1,799.16
    +34.34 (+1.95%)
     
  • Crude Oil

    110.76
    +0.43 (+0.39%)
     
  • Gold

    1,852.60
    +6.30 (+0.34%)
     
  • Silver

    22.00
    +0.13 (+0.59%)
     
  • EUR/USD

    1.0695
    -0.0042 (-0.40%)
     
  • 10-Yr Bond

    2.7490
    -0.0110 (-0.40%)
     
  • GBP/USD

    1.2585
    +0.0053 (+0.42%)
     
  • USD/JPY

    127.2550
    +0.4260 (+0.34%)
     
  • BTC-USD

    29,806.15
    +252.53 (+0.85%)
     
  • CMC Crypto 200

    659.93
    -11.08 (-1.65%)
     
  • FTSE 100

    7,522.75
    +38.40 (+0.51%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Down 57% in 1 Month, Is Novavax a Bargain Buy?

·4 min read
Down 57% in 1 Month, Is Novavax a Bargain Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

To say that Novavax (NASDAQ: NVAX) investors haven't had a smooth ride recently is a massive understatement. Amid a string of successes (and a few setbacks) in getting its coronavirus vaccine, Nuvaxovid approved by regulators in the European Union, South Korea, and with the World Health Organization, the company's stock has plummeted, falling around 55% compared to its price six months ago and 57% since a mere 30 days ago. Has the stock fallen enough to be worth a purchase based on the expectation of future jab sales and vaccine development, or should investors stay away for the time being?